KRTDAP: A Potential Drug Target and Biomarker (G388533)

Target Name: KRTDAP

NCBI ID: G388533

KRTDAP

KRTDAP: A Potential Drug Target and Biomarker

KRTDAP (KRTDAP variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is Kallikrein-related peptidase DAP (KLK1), which is a member of the serine proteases family 11. KRTDAP has been identified as a potential drug target and biomarker due to its unique structure, function, and expression pattern in various tissues.

The serine proteases are a group of enzymes that play a crucial role in cell signaling, tissue repair, and inflammation. These enzymes are involved in the degradation of various bioactive molecules, including peptides, neurotransmitters, and extracellular matrix (ECM) components. KLK1 is a member of the serine proteases family 11, which includes other enzymes such as Kallikrein, which is involved in the generation of adenosine, a signaling molecule that plays a role in various physiological processes.

KRTDAP is a 14-kDa protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is highly conserved, with a calculated molecular weight of 19,112. KRTDAP has a unique structure that consists of a catalytic active site, a regulatory region, and a carboxylic acid region.

The catalytic active site is the region that is responsible for the catalytic activity of KLK1. It contains a variable loop, a 尾-sheet, and a 纬-sheet, which are important structural elements that contribute to the stability and activity of the enzyme. The 尾-sheet is a repeating unit that contains the catalytic active site and is responsible for the formation of a disulfide bond. The 纬-sheet is a structural element that interacts with the 尾-sheet and contributes to the stability of the enzyme.

The regulatory region is the region that interacts with other proteins and molecules to regulate the activity of KLK1. It contains a N-terminal region that contains a leucine zipper, a conserved core, and a C-terminal region that contains a domain that interacts with the N-terminal region. The N-terminal region is responsible for interacting with the C-terminal region, which in turn interacts with the target protein.

The carboxylic acid region is the region that gives KRTDAP its unique structure and function. It consists of a single catalytic active site that is responsible for the catalytic activity of KLK1. The carboxylic acid region is important for the stability and activity of the enzyme because it includes a conserved aspartic acid residue that can participate in the formation of a disulfide bond.

KRTDAP has been identified as a potential drug target due to its unique structure, function, and expression pattern in various tissues. The protein is expressed in various tissues of the body, including the brain, heart, and kidneys, and has been shown to play a role in various physiological processes, including inflammation, fibrosis, and neurodegeneration.

In addition to its potential drug target properties, KRTDAP has also been identified as a biomarker for various diseases, including cancer, neurodegeneration, and fibrosis. The protein has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

KRTDAP has also been shown to be involved in various physiological processes that are important for human health, including inflammation and fibrosis. The protein has been shown to play a role in the regulation of inflammation, including the response of immune cells to

Protein Name: Keratinocyte Differentiation Associated Protein

Functions: May act as a soluble regulator of keratinocyte differentiation. May play an important role in embryonic skin morphogenesis

The "KRTDAP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTDAP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets